Straumann Holding AG
Straumann expands Executive Management and scales up to manage continuing growth
Corporate-news announcement processed and sent by DGAP.
The sender is solely responsible for the contents of this announcement.
——————————————————————————–
Straumann expands Executive Management and scales up to manage continuing
growth
– US and German Country Presidents complement executive team
– Marianne Bürgi joins from Synthes to head Market Support
Straumann, a global leader in implant dentistry and dental tissue
regeneration, announced today that it is adding three new positions to its
global executive management (currently six) to help master future expansion
and complexity. The changes will come into effect on 1 October 2004.
Having expanded rapidly since becoming a public company six years ago,
Straumann has transformed from a small family firm into a mid-size
international company. In the first half of this year, the Group increased
sales by 33% to CHF 217 million and created a further 102 new jobs worldwide,
lifting the total number of its employees to more than 1,000. Based on the
current trend, today’s workforce could double by the end of 2008.
“Our biggest current challenge is to absorb continued growth and to sustain
it by scaling up in a controlled manner. The senior appointments we are
announcing today will help direct and manage future expansion and
complexity”, said CEO Gilbert Achermann.
Executive management team strengthened
Wolfgang Becker, President of Straumann Germany, and Russ Olsen, President
of Straumann USA, both join the Executive Management, with Olsen assuming
responsibility for the North American region in addition to his current
duties. The CEO will continue to oversee the European region, while Thomas
Jaberg will concentrate on sales in the rest of the world including the
Asia-Pacific region and Straumann Distributors.
The other new executive position, Market Support, is filled by Marianne
Bürgi, who joins Straumann from Synthes. In the course of her career at
Synthes-Stratec, Marianne Bürgi spent a number of years in product and
project management before becoming a Business Unit Manager and Member of
the Executive Committee of Synthes-Stratec Europe and Latin America. She
was also on the Board of AO Spine Europe. She thus brings to Straumann a
wealth of product and senior management experience in the med-tech industry.
From the beginning of October, Straumann’s Executive Management will
comprise: Gilbert Achermann (CEO), Russ Olsen (Sales North America &
President Straumann USA), Wolfgang Becker (President Straumann Germany),
Thomas Jaberg (Sales RoW & Distributors), Markus Koller (Implants), Sandro
Matter (Biologics & Research), Marianne Bürgi (Market Support), Dieter Lipp
(Operations) and Martin Gertsch (Finance).
Disclaimer
This press release contains certain “forward-looking statements”, which can
be identified by the use of terminology such as “will”, “could”, “future”,
“accelerate,” “to meet”, “becoming”, or similar wording. Such
forward-looking statements reflect the current views of management and are
subject to known and unknown risks, uncertainties and other factors that
may cause actual results, performance or achievements of the Group to differ
materially from those expressed or implied. These include risks related to
the success of and demand for the Group’s products, the potential for the
Group’s products to become obsolete, the Group’s ability to defend its
intellectual property, the Group’s ability to develop and commercialize new
products in a timely manner, the dynamic and competitive environment in which
the Group operates, the regulatory environment, changes in currency exchange
rates, the Group’s ability to generate revenues and profitability, and the
Group’s ability to realize its expansion projects in Andover and Basel in a
timely manner. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual
results may vary materially from those described in this release. Straumann
is providing the information in this release as of this date and does not
undertake any obligation to update any forward-looking statements contained
in it as a result of new information, future events or otherwise.
Waldenburg, 26 August 2004
Contacts:
Gilbert Achermann, Chief Executive Officer
(+41) 061 965 1111
Mark Hill, Corporate Communication
(+41) 061 965 1321
About Straumann
Headquartered in Waldenburg, Switzerland, Straumann is a global leader in
implant dentistry and dental tissue regeneration. In collaboration with the
International Team for Implantology (ITI), leading clinics, research
institutes and universities, the Group researches, develops, produces and
distributes implants, instruments and tissue regeneration products for use in
tooth replacement solutions or to prevent tooth loss. Straumann also provides
training and services to the dental profession worldwide. Straumann’s implants
and instruments are manufactured in Switzerland, whilst its dental tissue
regeneration products are produced in Sweden. With affiliates in 14 countries
and distributors in 35, Straumann employs more than 1000 people worldwide. In
2003, the Group generated sales of CHF 344 million and a net income of
CHF 80 million.
Straumann Holding AG, Hauptstrasse 26, 4427 Waldenburg, Switzerland
Phone: +41 (0)61 965 11 11 / Fax: +41 (0)61 965 11 01
e-mail: investor.relations@straumann.com or info@straumann.com
Homepage: http://www.straumann.com
end of message, (c)DGAP 26.08.2004
——————————————————————————–
WKN: 914326; ISIN: CH0012280076; Index:
Listed: Freiverkehr in Berlin-Bremen, Frankfurt, München und Stuttgart; SWX
Swiss Exchange
261810 Aug 04
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found